Wallstent在非血栓性May-Thurner综合征腔内治疗中的释放挑战与并发症
前瞻性单中心队列纳入38例非血栓性May-Thurner综合征患者,行左髂总静脉支架置入,评估Wallstent释放相关现象。共置入41枚支架,技术成功率100%,缩短和滑移普遍但可术中处理,近端压缩2例、迁移2例均经腔内技术处理,症状VAS改善率100%,1年随访无支架血栓或再干预。
要点
- Wallstent缩短和滑移是器械驱动的可预测现象,而非不良事件。
- 支架迁移罕见但多因素,可经腔内技术成功处理。
- 基于器械行为的释放策略可提高手术控制和临床结局。
核心结论
- Wallstent在NT-MTS中的释放表现为一致的器械驱动机械行为,缩短和滑移应视为可预测现象而非不良事件。
- 支架迁移虽罕见但多因素,可有效经腔内技术处理。
- 基于行为的Wallstent释放方法可能改善手术控制和临床结局。
研究设计与样本
- 前瞻性单中心队列研究,纳入38例非血栓性May-Thurner综合征患者,均接受左髂总静脉支架置入。
- 系统评估释放相关现象,包括缩短、滑移、近端压缩和迁移。
- 临床结局采用症状评估和视觉模拟量表(VAS)评价,随访包括双功超声至12个月。
主要发现
- 共置入41枚Wallstent,技术成功率100%。
- 释放过程中普遍观察到缩短和不同程度支架滑移,均于术中处理。
- 近端支架压缩2例(5.3%),头侧和尾侧迁移各1例(2.6%),两例迁移均经腔内技术成功处理,无需外科干预。
- 有症状患者VAS完全或部分改善达100%,所有静脉溃疡愈合,平均愈合时间2.5个月。
- 1年随访期间未观察到支架血栓形成或再干预。
关键数值与推荐
- 近端支架压缩发生率5.3%(2/38例)。
- 头侧和尾侧支架迁移发生率各2.6%(1/38例)。
- 静脉溃疡平均愈合时间2.5个月。
- 技术成功率100%(41枚支架置入)。
临床怎么用
- 认识Wallstent缩短和滑移的可预测性,避免误判为不良事件。
- 释放时考虑合适尺寸选择、多平面静脉造影、在预定着陆区头侧约3 cm开始释放、必要时可控释放并重新定位。
- 确保病变完全覆盖,近端延伸至IVC汇合处上方数毫米,并由远及近行支架后扩张。
- 对于完全迁移至IVC内的Wallstent,可采用新型腔内技术处理而不中止原手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate Wallstent deployment challenges and complications during endovenous management of non-thrombotic May-Thurner syndrome (NT-MTS) and to define their underlying mechanisms and optimal management strategies. METHODS: This prospective single-center cohort study included 38 patients with NT-MTS treated with left common iliac vein stenting. Deployment-related phenomena, including foreshortening, slipping, proximal compression, and migration, were systematically assessed. Clinical outcomes were evaluated using symptom assessment and visual analog scale (VAS). Follow-up included duplex ultrasonography up to 12 months. RESULTS: A total of 41 Wallstents were deployed with 100% technical success. Foreshortening and varying degrees of stent slipping were consistently observed during deployment and were managed intra-procedurally. Proximal stent compression occurred in 2 cases (5.3%), whereas cranial and caudal migration each occurred in 1 case (2.6%). Both migration events were successfully managed using endovascular techniques without surgical intervention. Complete or partial VAS improvement was observed in 100% of symptomatic patients. All venous ulcers healed, with a mean healing time of 2.5 months. No stent thrombosis or reintervention was observed during 1-year follow-up. CONCLUSION: Wallstent deployment in NT-MTS is characterized by consistent, device-driven mechanical behavior, including foreshortening and slipping, which should be recognized as predictable rather than adverse events. Stent migration, although rare, is multifactorial and can be effectively managed using endovascular techniques. A behavior-based approach to Wallstent deployment may improve procedural control and clinical outcomes.Clinical ImpactThis study addresses the predictable mechanical behavior of Wallstents during treatment of May-Thurner syndrome and the technical challenges that may arise during deployment, as well as complications including cranial and caudal stent migration. Understanding these characteristics provides practical guidance for controlled stent deployment, including appropriate sizing, multiplanar venography, initiating deployment approximately 3 cm cranial to the intended landing zone, controlled release with repositioning when necessary, Complete lesion coverage with proximal extension a few millimeters above the IVC confluence and distal-to-proximal post-stent dilatation. The study also introduces a novel endovascular technique for managing a migrated Wallstent entirely within the IVC, allowing successful correction without aborting the primary procedure.
引用
- Zaied MM, Kamal M, Imam E, et al. Wallstent Deployment Challenges and Complications in Endovenous Management of Non-thrombotic May-Thurner Syndrome. J Endovasc Ther. 2026. PMID: 42773080. doi:10.1177/15266028261489161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。